title: Impact of a metabolic screening bundle on rates of screening for metabolic syndrome in a psychiatry resident outpatient clinic.
abstract: OBJECTIVE
  Although it is widely acknowledged that second-generation antipsychotics are associated with cardiometabolic side effects, rates of metabolic screening have remained low. The authors created a quality-improvement (QI) intervention in an academic medical center outpatient psychiatry resident clinic with the aim of improving rates of screening for metabolic syndrome in patients being prescribed antipsychotic medications.
  
  
  METHODS
  The core components of the QI intervention included resident education and creation of a metabolic screening bundle for the electronic medical record. Quarterly audits of individual patient electronic medical records assessed whether a patient was currently prescribed antipsychotics and whether metabolic-syndrome screening had been documented at any time in the preceding 12 months.
  
  
  RESULTS
  In each audit period, from 131 to 156 patients (30%-36% of total clinic sample) were prescribed antipsychotic medication. After the intervention, rates of documentation of the components of the metabolic screening bundle increased between 3.5- and 10-fold (final rates: 39% for blood pressure, 44% for BMI, and 55% for glucose and lipid panel). Rates of documenting the full bundle increased nearly 30-fold (final rate: 31%).
  
  
  CONCLUSIONS
  Provider-education combined with introduction of a documentation bundle in the electronic medical record increased rates of documented metabolic screening in patients being prescribed antipsychotic medications by psychiatry residents.
authors.affiliation: Dept. of Psychiatry, Massachusetts General Hospital, Boston, USA. ilse.wiechers@yale.edu
authors.forename: Ilse R
authors.initials: IR
authors.lastname: Wiechers
authors.forename: Mark
authors.initials: M
authors.lastname: Viron
authors.forename: Joseph
authors.initials: J
authors.lastname: Stoklosa
authors.forename: Oliver
authors.initials: O
authors.lastname: Freudenreich
authors.forename: David C
authors.initials: DC
authors.lastname: Henderson
authors.forename: Anthony
authors.initials: A
authors.lastname: Weiss
mesh_terms: D000046:Academic Medical Centers; D000328:Adult; D000554:Ambulatory Care Facilities; D014150:Antipsychotic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007396:Internship and Residency; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000175:diagnosis*; D010045:Outpatients; D010818:Practice Patterns, Physicians'; D011570:Psychiatry / Q000193:education*; D011785:Quality Assurance, Health Care / Q000379:methods*; D058996:Quality Improvement
chemical_list: D014150:Antipsychotic Agents